Skip to main content

Market Overview

Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

Share:
Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study
  • Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer.
  • The results will be presented as a poster at the AACR Annual Meeting 2021.
  • In the study, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients.
  • No dose-limiting toxicities were observed, and all adverse events were readily manageable.
  • The Phase 1 study was designed to determine the safety and recommended Phase 2 dose of ifabotuzumab.
  • Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting the EphA3 receptor. EphA3 is a tumor-restricted antigen expressed in the tumor vasculature and tumor stroma of various solid tumors.
  • Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.
  • Price Action: HGEN shares are trading 2.8% higher at $17.4 in the premarket session on the last check Friday.
 

Related Articles (HGEN)

View Comments and Join the Discussion!

Posted-In: brain cancer BriefsBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com